www.fdanews.com/articles/81233-wex-restructuring
WEX RESTRUCTURING
September 28, 2005
WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) today announced that it has undertaken a restructuring to reduce its costs. In connection with the restructuring the headcount has been reduced by about 35% in both its headquarters in Vancouver and its Hong Kong Office. After giving effect to restructuring costs, the headcount reduction is expected to reduce employment and related expenses by approximately 30%. The company's search for a new CEO is ongoing.
CCNMatthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&actionFor=556792)